{"disease":{"id":"mf","name":"mf"},"drugs":{"marketed":[{"drug_id":"chlorothiazide","indication_name":"Severe Discomforting Edema in Pregnancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"propylene-glycol-0-3","indication_name":"Minor Eye Discomfort Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Propylene Glycol 0.3%","company_name":"Innovative Medical","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"ozone","indication_name":"head discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pollutox","generic_name":"OZONE","company_name":"Deseret Biologicals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Radiographic Contrast Agent [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"ozone","indication_name":"abdominal discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pollutox","generic_name":"OZONE","company_name":"Deseret Biologicals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Radiographic Contrast Agent [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"borneol","indication_name":"discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hemorrhoid, Fissure, ProctalgiaSuppositories","generic_name":"BORNEOL","company_name":"WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Chemical Allergen [EPC]","quality_score":28,"revenue":null,"mechanism":"Proctalgia Suppositories works by interacting with the anal tissue to reduce symptoms of irritation, pain, and discomfort."},{"drug_id":"influenza-and-covid-19-combination-a","indication_name":"discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Influenza","generic_name":"Influenza and COVID-19 Combination A","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein and influenza hemagglutinin protein","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Primary Myelofibrosis (PMF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"influenza-and-covid-19-combination-b","indication_name":"discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Influenza","generic_name":"Influenza and COVID-19 Combination B","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"vaccination","indication_name":"skin discomfort","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Post - Vaccination","generic_name":"vaccination","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"Inactivated Poliovirus Vaccine [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"real-word-drugs","indication_name":"Familial Mediterranean Fever (FMF )","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"real word drugs","generic_name":"real-word-drugs","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"real word drugs","quality_score":0,"revenue":null,"mechanism":"real word drugs"}],"offLabel":[],"totalMarketed":39,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT00001373","title":"Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT06579950","title":"Assessing the Effects of Cool Roofs on Indoor Environments and Health","phase":"NA","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Aditi Bunker","has_results":false},{"nct_id":"NCT06452303","title":"The Patient Cohort for Bariatric Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03517878","title":"Evaluation of a Home-based Community Health Worker Program in Rural Eastern Cape, South Africa","phase":"","overall_status":"COMPLETED","enrollment_count":1490,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT04147520","title":"Reducing Hazardous Alcohol Use in Social Networks Using Targeted Intervention: 21 Rising","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1475,"lead_sponsor_name":"Brown University","has_results":false},{"nct_id":"NCT03488927","title":"Development and Pilot Trial of an Intervention to Reduce Disclosure Recipients Negative Social Reactions and Victims Psychological Distress and Problem Drinking","phase":"NA","overall_status":"COMPLETED","enrollment_count":1268,"lead_sponsor_name":"University of New Hampshire","has_results":true},{"nct_id":"NCT02377726","title":"Anonymous Treatment on the Internet for Alcohol Dependence: A Randomised, Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":1170,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT07488468","title":"Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT07457957","title":"Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":874,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06569836","title":"Evaluation Study for the \"Jockey Club E-Generation: Impact Extension Project for Chronic Knee Pain Management\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":858,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06834893","title":"Assessing the Effects of Cool Roofs on Indoor Environments and Health in Colima, Mexico","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Aditi Bunker","has_results":false},{"nct_id":"NCT03467191","title":"Behavioral Alcohol Responses (BAR) Study","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":782,"lead_sponsor_name":"Carnegie Mellon University","has_results":false},{"nct_id":"NCT03696888","title":"Skills-training for Reducing Risky Alcohol Use in App Form","phase":"NA","overall_status":"COMPLETED","enrollment_count":678,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03449095","title":"Understanding Alcohol Reward in Social Context","phase":"NA","overall_status":"COMPLETED","enrollment_count":640,"lead_sponsor_name":"University of Illinois at Urbana-Champaign","has_results":true},{"nct_id":"NCT04381104","title":"Strategy to Cope Pain and Discomfort in Mammography","phase":"NA","overall_status":"UNKNOWN","enrollment_count":632,"lead_sponsor_name":"Dow University of Health Sciences","has_results":false},{"nct_id":"NCT06479135","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07280624","title":"Diagnostic PCR Panel in Children With Acute Gastrointestinal Symptoms","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":526,"lead_sponsor_name":"University of Oulu","has_results":false},{"nct_id":"NCT03884478","title":"A Gamified, Social Media Inspired Personalized Normative Feedback Alcohol Intervention for Sexual Minority Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Loyola Marymount University","has_results":true},{"nct_id":"NCT03928886","title":"Discomfort Assessment of Senographe Pristina Patient-assisted Versus Standard Compression Mode and Quality Assessment of Screening Mammograms","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Parc de Salut Mar","has_results":false},{"nct_id":"NCT04552171","title":"Game Plan: Efficacy of a Brief, Web-based Intervention on Alcohol Use and Sexually-transmitted Infections","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Brown University","has_results":false},{"nct_id":"NCT07357727","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02758054","title":"Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System","phase":"NA","overall_status":"COMPLETED","enrollment_count":447,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03072394","title":"Local Anesthesia in Radial Catheterization","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":444,"lead_sponsor_name":"Hippocration General Hospital","has_results":false},{"nct_id":"NCT03521115","title":"Family Based Prevention of Alcohol and Risky Sex for Older Teens","phase":"NA","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"Pacific Institute for Research and Evaluation","has_results":true},{"nct_id":"NCT05886101","title":"Increase Health Literacy Through Health Education to Improve Menstruation Related Self-care and Work Productivity","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Hiroshima University","has_results":false},{"nct_id":"NCT03662126","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":385,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04594304","title":"Screening While You Wait 2: Alcohol and Tobacco Use","phase":"NA","overall_status":"UNKNOWN","enrollment_count":360,"lead_sponsor_name":"Women's College Hospital","has_results":false},{"nct_id":"NCT05128877","title":"The Effectiveness of Relaxation Training on Primary Dysmenoreh and Menstrual Symptoms","phase":"NA","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"Cukurova University","has_results":false},{"nct_id":"NCT03504449","title":"Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Beijing Chao Yang Hospital","has_results":false},{"nct_id":"NCT01195337","title":"Social Contextual Influences on Physical Activity","phase":"","overall_status":"UNKNOWN","enrollment_count":336,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07163637","title":"Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort","phase":"NA","overall_status":"RECRUITING","enrollment_count":324,"lead_sponsor_name":"Novozymes A/S","has_results":false},{"nct_id":"NCT04428164","title":"Enhancing Patient Experience of Pain and Sleep Through Non-Pharmacological Strategies","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT02888002","title":"Internet-based vs Face-to-face Treatment for Alcohol Dependence","phase":"NA","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05863156","title":"Evaluation of the Effects of Different Positions Given During Antenatal Electro-Fetal Monitoring","phase":"NA","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"Uskudar University","has_results":true},{"nct_id":"NCT06053008","title":"The Relationship Between Pain Perception, Severity of Temporomandibular Joint Dysfunction, and Spinal Health in Geriatric Individuals","phase":"NA","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Tokat Gaziosmanpasa University","has_results":false},{"nct_id":"NCT07329556","title":"Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bursa City Hospital","has_results":false},{"nct_id":"NCT06570993","title":"Assessing the Effects of Cool Roofs on Indoor Environments and Health in Niue","phase":"NA","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Aditi Bunker","has_results":false},{"nct_id":"NCT07498205","title":"Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":268,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07419178","title":"A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept","phase":"NA","overall_status":"RECRUITING","enrollment_count":265,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Parma","has_results":false},{"nct_id":"NCT06286774","title":"Sleep as a Mechanism of Change in Alcohol Use","phase":"NA","overall_status":"RECRUITING","enrollment_count":256,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT05060536","title":"Infrapatellar Fat Pad Excision in Total Knee Arthroplasty","phase":"NA","overall_status":"UNKNOWN","enrollment_count":256,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT04472598","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06967116","title":"Impact of Urinary Catheter Fixation on Meatal Pressure Injury in Male Patients in the Intensive Care Unit","phase":"NA","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Merve Zorlu","has_results":false},{"nct_id":"NCT07493785","title":"Dexmedetomidine for Invasive Ventilation In the NEOnate","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":246,"lead_sponsor_name":"Centre Hospitalier Intercommunal Creteil","has_results":false},{"nct_id":"NCT06687525","title":"Alcohol and the Social Brain: an Alcohol-Administration Hyperscanning Study","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"University of Illinois at Urbana-Champaign","has_results":false},{"nct_id":"NCT05089318","title":"Evaluation of Flexofytol® PLUS in Hand Joint Chronic Dyscomfort.","phase":"","overall_status":"COMPLETED","enrollment_count":239,"lead_sponsor_name":"Tilman S.A.","has_results":false},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06877663","title":"Virtual Reality on Anxiety Management During Elective Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"University of Campania Luigi Vanvitelli","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}